(1) Intelligent/multi-functional nano-formulation technology

(2) Biomacromolecule delivery technology

(3) Design of functionalized pharmaceutical materials

1. Research Projects

(1) Step-by-Step Tumor-Infiltrating and Multi-Target Co-Triggered Tinibs-Nanodrugs; National Natural Science Foundation of China (General Program), NO. 81972835, 2020/01-2023/12, Principal Investigator

(2) Outstanding Young Backbone Teacher of Jiangsu Province, Jiangsu Provincial Department of Education, 2020/06-2023/06, Principal Investigator

(3) Intelligent Temporally Controlled Nanodrugs for Homogeneous Tumor Drug Resistance Reversal; Key Program of Fundamental Research Funds for the Central Universities, NO. 2632019ZD06, 2018/01-2020/12, Principal Investigator

(4) Sequential Delivery of Drug-Resistance Reversal Agents and Chemotherapeutics by Tumor-Penetrating Mineralized Graphene Nanosheets for An Effective and Homogeneous Treatment of Drug-Resisitant Tumor; National Natural Science Foundation of China (Young Scholar Fund), No. 81703442; 2018/01-2020/12. Principal Investigator

(5) Tumor Microenvironment Remodulation-Based PSCs-Targeting Formulations for Advanced Pancreatic Cancer Chemotherapy Sensitization and Corresponding Mechanism Investigation; National Natural Science Foundation of China (General Program), NO. 81872424; 2019/01-2022/12, Major Participator

(6) “Stem Cells-like Nanoparticles” Drug Delivery System for Neurorestoration; National Natural Science Foundation of China (General Program), NO. 81872819; 2019/01-2022/12, Major Participator

(7) Key Technology and Standard Criteria of Drug Consistency Evaluation-Subproject 4: BCS and IVIVC-Based Bioequivalence Exemption Investigation; National Science and Technology Major Project, Participator

2. Academic Awards

2018/01 Second Prize for Scientific and Technological Progress of Jiangsu Province (7/7)

3. Representative Research Achievements

(1) The research began with the construction of microenvironment-responsive multifunctional polymeric drugs, applying the responsive drug release technology to the tumor-targeting single-drug therapy and multi-drug co-delivery combination therapy. Multiple drug rapid release was aimed to realize the enhancement of single or combined drugs pharmaceutical effects, as well as explore the correlation of target site-specific triggered drug release kinetics and pharmaceutical effects. Relevant achievements have been published in hallmark journals of pharmacy and materials science, including J Control Release 2016, Biomaterials 2015, ACS Appl Mater Inter 2018, etc.

(2) Currently, investigations are especially focused on the lesion-targeted, spatiotemporally controlled release drug delivery systems. Among them, strategies to enhance permeation through cellular transport barriers (such as membranes and subcellular organelles) have been partially published in Adv Funct Mater 2017. The strategies of step-by-step infiltration enhancement through tissue transport barriers as well as “temporally controlled drug release” for heterotopic multiple target are under investigations for diseases such as tumors and inflammations. Some achievements have been published in J Control Release 2020, 2021, Biomaterials 2021, etc.

1. Huo, M.R.; Zhou, J.Y.; Wang, H.L.; Zheng, Y.Z.; Tong, Y.Q.; Zhou, J.P.*; Liu, J.Y.; Yin, T.J.* A pHe sensitive nanodrug for collaborative penetration and inhibition of metastatic tumors. J Control Release. 2022; 352: 893-908. (IF: 11.467)

2. Wang, H.L.; Zhou, J.Y.; Fu, Y.; Zheng, Y.Z.; Shen, W.Y.*; Zhou, J.P.*; Yin, T.J.* Deeply Infiltrating iRGD-Graphene Oxide for the Intensive Treatment of Metastatic Tumors through PTT-Mediated Chemosensitization and Strengthened Integrin Targeting-Based Antimigration. Adv Healthc Mater. 2021;10(16):e2100536. (IF: 11.092)

3. Huo, M.R.; Wang, H.L.; Li, L.C.; Tong, Y.Q.; Hu C.X.; Gu, Y.W.; Liu, J.Y.*; Yin T.J.* Redox-sensitive hyaluronic acid-cholesterol nanovehicles potentiate efficient transmembrane internalization and controlled release for penetrated full-line inhibition of pre-metastatic initiation. J Control Release. 2021;336:89-104. (IF: 11.467)

4. Liu, Y.H.; Zhou, J.Y.; Li, Q.; Li L.C.; Jia, Y.; Geng, F.Y.; Zhou, J.P.*; Yin. T.J.* Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma. Advanced Drug Delivery Reviews. 2021;172:80-103. (IF: 17.873)

5. Liu, Y.H.; Li, L.C.; Liu, J.Y.; Yang, M.N.; Wang, Ho.L.; Chu, X.X.; Zhou, J.P.*; Huo, M.R.*; Yin, T.J.* Biomineralization-inspired dasatinib nanodrug with sequential infiltration for effective solid tumor treatment. Biomaterials. 2021;267:120481. (IF: 15.304)

6. Huo, M.R.; Wang, H.L.; Zhang, Y.; Cai, H.; Zhang, P.; Li, L.C.; Zhou, J.P.*; Yin, T.J.* Co-delivery of silybin and paclitaxel by dextran-based nanoparticles for effective anti-tumor treatment through chemotherapy sensitization and microenvironment modulation. Journal of Controlled Release. 2020;321:198-210. (IF: 9.776)

7. Yin, T.J.; Liu, Y.Q.; Yang, M.N.; Wang, L.; Zhou, J.P.*; Huo, M.R.* Novel Chitosan Derivatives with Reversible Cationization and Hydrophobicization for Tumor Cytoplasm-Specific Burst Co-delivery of siRNA and Chemotherapeutics. ACS Applied Materials & Interfaces. 2020;12(13):14770-14783. (IF: 9.229)

8. Yin, T.J.; Wang, Y.Y.; Chu, X.X.; Fu, F.; Wang, L.; Zhou, J.P.; Tang, X.M.; Liu, J.Y.*; Huo, M.R.* Free adriamycin-loaded pH/reduction dual-responsive hyaluronic acid–adriamycin prodrug micelles for efficient cancer therapy. ACS Applied Materials & Interface.  2018;10(42):35693-35704. (IF:8.456)

9. Yin, T.J.; Liu, J.Y.; Zhao, Z.K.; Zhao, Y.Y.; Dong, L.H.; Yang, M; Zhou, J.P.*; Huo, M.R.* Redox Sensitive Hyaluronic Acid-Decorated Graphene Oxide for Photothermally Controlled Tumor-Cytoplasm Selective Rapid Drug Delivery. Advanced Functional Materials. 2017;27(14):1604620. (IF: 13.325)

10. Yin, T.J.; Liu, J.Y.; Zhao, Z.K.; Dong, L.H.; Cai, H.; Yin, L.F.; Zhou, J.P.*; Huo, M.R.* Smart nanoparticles with a detachable outer shell for maximized synergistic antitumor efficacy of therapeutics with varying physicochemical properties. Journal of Controlled Release. 2016;243:54-68. (IF: 7.727)

Ph.D. Candidate

Jiyuan Zhou (2021 enrolled)

Yuzhao Zheng, Mengnan Yang (2023 enrolled)

Postgraduate Student

Mengnan Yang, Wenna Feng, Yuzhao Zheng, Yue Jia, Zongyao Cui, Jingjing Yuan (2020 enrolled)

Yu qi, Tongyu Wu, Ruyu Lv, Yitong Yang, Yurou Wang (2021 enrolled)

Xin Zhang, Xiangling Yang, Mengfei Ji, Yidian Wang, Xiaolin Huang, Jiaxin Li (2022 enrolled)